WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical
device provider, today announced that it will be participating in the
following upcoming investor conferences:
The 2013 Canaccord Genuity Medical Technology & Diagnostics Forum at
the Westin Grand Central Hotel in New York on November 14, 2013.
The Piper Jaffray 2013 Annual Health Care Conference at the New York
Palace Hotel on December 4, 2013.
About AtriCure, Inc.
AtriCure, Inc. is a leading atrial fibrillation solutions partner,
providing innovative products, professional education and support for
clinical science to reduce the economic and social burden of atrial
fibrillation. AtriCure's Synergy Ablation System is the first and only
device approved by the Food and Drug Administration (FDA) for the
surgical treatment of Persistent and Longstanding Persistent forms of
Afib in patients undergoing certain open heart procedures concomitantly
(simultaneously). AtriCure's AtriClip™ Left Atrial Appendage
(LAA) occlusion device is the most widely implanted device for LAA
management worldwide. Afib affects more than two million people
worldwide and is estimated to cost more than $6.5 billion annually in
healthcare expenses. The number affected by Afib is expected to grow to
12 million by 2050.
Source: AtriCure, Inc.
Andy Wade, Vice President and Chief Financial
Lynn Pieper, 415-202-5678